About
About Mangalam Drugs & Organics Limited
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it offers organic and inorganic chemicals and heavy chemicals; and offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.
Visit company website
5 years, 4 months ago
Mangalam Drugs & Organics Limited is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.
From a valuation standpoint, the stock is 89.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.5.
Mangalam Drugs & Organics Limited's total revenue sank by 71.3% to $887M since the same quarter in the previous year.
Its net income has dropped by 48.3% to $64M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $81M since the same quarter in the previous year.
Based on the above factors, Mangalam Drugs & Organics Limited gets an overall score of 2/5.